A Clinical Trial Comparing the Sustained Virological Response in Terms of Expression Profile of IL- 28B in Genotype 1 HCV-Infected Treatment-Naïve Subjects With Chronic Hepatitis C on Pegasys (Peginterferon Alfa-2A) Plus Copegus(Ribavirin)
Phase of Trial: Phase IV
Latest Information Update: 29 Jun 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 23 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 May 2013 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.